Kala Pharmaceuticals Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
Kala Pharmaceuticals (KALA) Tops Q2 EPS by 3c
August 6, 2019 7:58 AM EDTKala Pharmaceuticals (NASDAQ: KALA) reported Q2 EPS of ($0.70), $0.03 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $2.69 million.
For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.
... More